Skip to main content
Equibles
EVFM logo

EVFM · Evofem Biosciences, Inc.

Track EVFM — free

Use EVFM with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about EVFM

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$0.01 +0.00 (+7.04%) At close · Aug 18
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“The Company has concluded that these circumstances and the uncertainties associated with the Company's ability to obtain additional equity or debt financing on terms that are favorable to the Company, or at all, and otherwise succeed in its future operations raise substantial doubt about the Company's ability to continue as a going concern.”
View the 10-Q filed Aug 14, 2026
Market Cap
$940,963
Shares
132.53M

Evofem Biosciences, Inc. Earnings Call Transcripts

Every quarterly earnings call for Evofem Biosciences, Inc. (EVFM) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
· $ −$19.15M '20 Q1 20-05-06 · $ −$52.67M '20 Q2 20-08-04 · $278,000 −$29.90M '20 Q3 20-11-09 · $168,000 −$40.60M '20 Q4 21-03-04 · $1.10M −$46.15M '21 Q1 21-05-06 · $1.86M −$33.43M '21 Q2 21-08-11 ▲2025% $3.57M −$51.55M '21 Q4 22-03-03 ▲284.7% $4.25M −$31.89M '22 Q1 22-05-04 LATEST ▲224.9% $6.03M −$125.98M '22 Q2 22-08-04
Earnings call
FY22 · Q2
2022-08-04
Evofem Biosciences, Inc. Q2 FY2022 Earnings Call
Revenue
$6.03M
▲ 224.9% YoY
Diluted EPS
$-580.48
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Evofem Biosciences, Inc. Q1 FY2022 Earnings Call
Revenue
$4.25M
▲ 284.7% YoY
Diluted EPS
$-360.00
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q4
2022-03-03
Evofem Biosciences, Inc. Q4 FY2021 Earnings Call
Revenue
$3.57M*
▲ 2025% YoY
Rev · 7q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY21 · Q2
2021-08-11
Evofem Biosciences, Inc. Q2 FY2021 Earnings Call
Revenue
$1.86M
Diluted EPS
$-501.25
Rev · 6q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY21 · Q1
2021-05-06
Evofem Biosciences, Inc. Q1 FY2021 Earnings Call
Revenue
$1.10M
Diluted EPS
$-1057.50
Rev · 5q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q4
2021-03-04
Evofem Biosciences, Inc. Q4 FY2020 Earnings Call
Revenue
$168,000*
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY20 · Q3
2020-11-09
Evofem Biosciences, Inc. Q3 FY2020 Earnings Call
Revenue
$278,000
Diluted EPS
$-693.75
Rev · 4q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q2
2020-08-04
Evofem Biosciences, Inc. Q2 FY2020 Earnings Call
Revenue
$
Diluted EPS
$-1706.25
Rev · 3q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY20 · Q1
2020-05-06
Evofem Biosciences, Inc. Q1 FY2020 Earnings Call
Revenue
$
Rev · 2q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY19 · Q4
2020-03-12
Evofem Biosciences, Inc. Q4 FY2019 Earnings Call
Results not yet reported
Audio Transcript Slides 8-K10-K
Showing 1–10 of 10 earnings calls
Key facts CIK 1618835 CUSIP 30048L302 13F (30d) 1 filings 1 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)